Ignite Creation Date:
2024-05-05 @ 5:25 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00453492
Status:
COMPLETED
Last Update Posted:
2008-03-11
First Post:
2007-03-28
Brief Title:
Risedronate Sodium in Post Menopausal Osteoporosis
Sponsor:
Sanofi
Organization:
Sanofi
Study Overview
Official Title:
A Multicenter Prospective Randomized 2-Way Crossover Open-Label Study pn Postmenopausal Women With Osteoporosis Examining Subject Satisfaction and Compliance When Risedronate Sodium Actonel in Administered 35mg Once a Week or 5mg Once Daily
Status:
COMPLETED
Status Verified Date:
2008-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective is to compare subject satisfaction of once a week dosing of 35 mg Actonel to once daily dosing of 5 mg Actonel in postmenopausal osteoporotic women
The secondary objectives are to measure compliance 50 drug taken and persistence and urinary NTx N-telopeptides optional
The secondary objectives are to measure compliance 50 drug taken and persistence and urinary NTx N-telopeptides optional
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None